News & Insights
NY CCB Meeting Update 9/12/23 – Board Adopts General Adult-Use Regulations
Today’s New York State Cannabis Control Board (CCB) Meeting brought forth significant and long waited developments to the state’s cannabis landscape. The CCB authorized the State’s general adult-use regulations which will enable the much-anticipated general adult-use market to initiate its licensing application process, which is scheduled to commence on October 4th.
U.S. HHS Recommends Cannabis Move to Schedule III of the Controlled Substances Act
On August 30, 2023, the U.S. Department of Health and Human Services (HHS) recommended to the U.S. Drug Enforcement Administration (DEA) that cannabis, currently a schedule I controlled substance, be reclassified as a schedule III controlled substance under U.S. federal law. This recommendation, if adopted by the DEA, could have a monumental impact on the U.S. state legal cannabis industry.
Bipartisan Legislation Introduced to Regulate Hemp-Derived CBD
On July 20, 2023, the Hemp Access and Consumer Safety Act was reintroduced in the U.S. Congress. The long-awaited legislation, originally introduced in 2021, would require the U.S. Food and Drug Administration (FDA) to regulate ingestible hemp-derived cannabidiol (CBD) products the same as other foods, beverages, and dietary supplements.
Understanding the FDA’s New Guidelines for Psychedelic Drug Development and Research
The Food and Drug Administration (FDA) released draft guidance for researchers to consider when conducting clinical trials of the therapeutic benefits of psychedelic drugs.
